Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study

Oncologist

Volumn 18, Issue 7, 2013, Pages 795-801

  Bonifazi, Martina ^a   Franchi, Matteo ^a   Rossi, Marta ^a,b   Moja, Lorenzo ^b,c   Zambelli, Alberto ^d   Zambon, Antonella ^e   Corrao, Giovanni ^e   La Vecchia, Carlo ^a,b   Zocchetti, Carlo ^f   Negri, Eva ^a  

^a Istitudo di Ricovero e Cura a Carattere Scientifico Multimedia Scientific and Technology Pole   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f Operative Unit of Territorial Health Services   (Italy)

Author keywords

Adjuvant chemotherapy; Cardiotoxicity; Early breast cancer; Survival; Trastuzumab

Indexed keywords

PACLITAXEL; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DEATH; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART RATE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; DISEASE FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART DISEASES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84880653442     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0065     Document Type: Article

References (29)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244: 707-712.
2. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-976.
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
4. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
6. Agenzia Italiana del Farmaco. Estensione delle indicazioni terapeutiche della specialita' medicinale Herceptin (trastuzumab), autorizzata con decisione della Commissione europea in data 22 maggio 2006 (Determinazione/C n. 100/2006). Available at http://antineoplastici.agenziafarmaco.it/herceptin_08_2006.pdf. Accessed June 26, 2013.
7. Moja L, Tagliabue L, Balduzzi S et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4: CD006243.
8. Tarantini L, Cioffi G, Gori S et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in realworld women with breast cancer. J Card Fail 2012; 18:113-119.
9. Serrano C, Cortes J, De Mattos-Arruda L et al. Trastuzumab-related cardiotoxicity in the elderly:A role for cardiovascular risk factors. Ann Oncol 2012; 23:897-902.
10. Vicente C, Serrano N, Agustin MJ et al. Cardiotoxicity associated with trastuzumab in normal clinical practice. Farm Hosp 2009;33:202-207.
11. Tarantini L, Gori S, Faggiano P et al. Adjuvant trastuzumab cardiotoxicity in patients over60years of age with early breast cancer: A multicenter cohort analysis. Ann Oncol 2012;23:3058-3063.
12. Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 2012;104:1293-1305.
13. Bonifazi M, Rossi M, Moja L et al. Bevacizumab in clinical practice: Prescribing appropriateness relative to national indications and safety. The Oncologist 2012;17:117-124.
14. Ragazzo C. Giornale Italiano di Health Technology Assessment. 2009;2:119-126.
15. Grimaldi PL, Micheletti JA. Diagnosis related groups: A practitioner's guide. Chicago, IL: Pluribus Press, 1983.
16. Corrao G, Scotti L, Zambon A et al. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach basedonadministrative databases. Atherosclerosis 2011;217:479-485.
17. Corrao G, Romio SA, Zambon A et al. Multiple outcomesassociated with theuseofmetforminand sulphonylureas in type 2 diabetes: A populationbased cohort study in Italy. Eur J Clin Pharmacol 2011;67:289-299.
18. Corrao G, Parodi A, Nicotra F et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29: 610-618.
19. Wadhwa D, Fallah-Rad N, Grenier D et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study. Breast Cancer Res Treat 2009;117: 357-364.
20. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007;357: 94-95.
21. New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston, MA: Little Brown, 1973.
22. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
23. Sawyer DB, Zuppinger C, Miller TA et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002; 105:1551-1554.
24. Zhao YY, Sawyer DR, Baliga RR et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998;273:10261-10269.
25. Associazione Italiana di Oncologia Medica. Linee guida neoplasia della mammella. Available at http://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/linee+guida/Neoplasie+della+mammella/1,1982,0. Accessed June 26, 2013.
26. Procter M, Suter TM, de Azambuja E et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28:3422-3428.
27. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-1238.
28. Papanikolaou PN, Christidi GD, Ioannidis JP. Patient outcomes with teaching versus nonteaching healthcare: A systematic review. PLoS Med 2006;3:e341.
29. Zambelli A, Della Porta MG, Eleuteri E et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast 2011;20: 176-183.